These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1040 related articles for article (PubMed ID: 31961766)
21. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. How JA; Patel S; Fellman B; Lu KH; Hwu P; Ramondetta LM; Westin SN; Fleming ND; Soliman PT; Jazaeri AA Gynecol Oncol; 2021 Jul; 162(1):24-31. PubMed ID: 33958211 [TBL] [Abstract][Full Text] [Related]
22. Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma. Fishman MN; Srinivas S; Hauke RJ; Amato RJ; Esteves B; Cotreau MM; Strahs AL; Slichenmyer WJ; Bhargava P; Kabbinavar FF Eur J Cancer; 2013 Sep; 49(13):2841-50. PubMed ID: 23726267 [TBL] [Abstract][Full Text] [Related]
23. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Albiges L; Gurney H; Atduev V; Suarez C; Climent MA; Pook D; Tomczak P; Barthelemy P; Lee JL; Stus V; Ferguson T; Wiechno P; Gokmen E; Lacombe L; Gedye C; Perini RF; Sharma M; Peng X; Lee CH Lancet Oncol; 2023 Aug; 24(8):881-891. PubMed ID: 37451291 [TBL] [Abstract][Full Text] [Related]
24. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970 [TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial. Matsubara N; de Wit R; Balar AV; Siefker-Radtke AO; Zolnierek J; Csoszi T; Shin SJ; Park SH; Atduev V; Gumus M; Su YL; Karaca SB; Cutuli HJ; Sendur MAN; Shen L; O'Hara K; Okpara CE; Franco S; Moreno BH; Grivas P; Loriot Y Eur Urol; 2024 Mar; 85(3):229-238. PubMed ID: 37778952 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial. Xu L; Chen J; Liu C; Song X; Zhang Y; Zhao H; Yan S; Jia W; Wu Z; Guo Y; Yang J; Gong W; Ma Y; Yang X; Gao Z; Zhang N; Zheng X; Li M; Su D; Chen M BMC Med; 2024 Apr; 22(1):172. PubMed ID: 38650037 [TBL] [Abstract][Full Text] [Related]
27. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Taylor MH; Schmidt EV; Dutcus C; Pinheiro EM; Funahashi Y; Lubiniecki G; Rasco D Future Oncol; 2021 Feb; 17(6):637-648. PubMed ID: 33300372 [TBL] [Abstract][Full Text] [Related]
28. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Kawazoe A; Xu RH; García-Alfonso P; Passhak M; Teng HW; Shergill A; Gumus M; Qvortrup C; Stintzing S; Towns K; Kim TW; Shiu KK; Cundom J; Ananda S; Lebedinets A; Fu R; Jain R; Adelberg D; Heinemann V; Yoshino T; Elez E; J Clin Oncol; 2024 Aug; 42(24):2918-2927. PubMed ID: 38833658 [TBL] [Abstract][Full Text] [Related]
29. Lenvatinib plus Pembrolizumab Combination Therapy for Advanced or Recurrent Endometrial Cancer: A Single-Center, Retrospective Analysis. Tochigi M; Shigeta S; Shimada M; Miyahara S; Hasegawa-Minato J; Shibuya Y; Ishibashi M; Hashimoto C; Tokunaga H; Yaegashi N Tohoku J Exp Med; 2024 Feb; 262(2):85-95. PubMed ID: 38008437 [TBL] [Abstract][Full Text] [Related]
30. Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Nishio M; Horai T; Horiike A; Nokihara H; Yamamoto N; Takahashi T; Murakami H; Yamamoto N; Koizumi F; Nishio K; Yusa W; Koyama N; Tamura T Br J Cancer; 2013 Aug; 109(3):538-44. PubMed ID: 23860537 [TBL] [Abstract][Full Text] [Related]
31. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Hong DS; Kurzrock R; Falchook GS; Andresen C; Kwak J; Ren M; Xu L; George GC; Kim KB; Nguyen LM; O'Brien JP; Nemunaitis J Oncotarget; 2015 Dec; 6(40):43127-34. PubMed ID: 26503473 [TBL] [Abstract][Full Text] [Related]
32. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Grünwald V; Powles T; Choueiri TK; Hutson TE; Porta C; Eto M; Sternberg CN; Rha SY; He CS; Dutcus CE; Smith A; Dutta L; Mody K; Motzer RJ Future Oncol; 2019 Mar; 15(9):929-941. PubMed ID: 30689402 [TBL] [Abstract][Full Text] [Related]
33. A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors. Kitano S; Fujiwara Y; Shimizu T; Iwasa S; Yonemori K; Kondo S; Shimomura A; Koyama T; Ebata T; Ikezawa H; Hayata N; Minoshima Y; Miura T; Kubota T; Yamamoto N Cancer Chemother Pharmacol; 2022 Dec; 90(6):523-529. PubMed ID: 36289094 [TBL] [Abstract][Full Text] [Related]
34. High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. Lee CH; DiNatale RG; Chowell D; Krishna C; Makarov V; Valero C; Vuong L; Lee M; Weiss K; Hoen D; Morris L; Reznik E; Murray S; Kotecha R; Voss MH; Carlo MI; Feldman D; Sachdev P; Adachi Y; Minoshima Y; Matsui J; Funahashi Y; Nomoto K; Hakimi AA; Motzer RJ; Chan TA Mol Cancer Res; 2021 Sep; 19(9):1510-1521. PubMed ID: 34039647 [TBL] [Abstract][Full Text] [Related]
35. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. Motzer RJ; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Alekseev B; Rha SY; Merchan J; Goh JC; Lalani AA; De Giorgi U; Melichar B; Hong SH; Gurney H; Méndez-Vidal MJ; Kopyltsov E; Tjulandin S; Gordoa TA; Kozlov V; Alyasova A; Winquist E; Maroto P; Kim M; Peer A; Procopio G; Takagi T; Wong S; Bedke J; Schmidinger M; Rodriguez-Lopez K; Burgents J; He C; Okpara CE; McKenzie J; Choueiri TK; J Clin Oncol; 2024 Apr; 42(11):1222-1228. PubMed ID: 38227898 [No Abstract] [Full Text] [Related]
36. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506 [TBL] [Abstract][Full Text] [Related]
37. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725 [TBL] [Abstract][Full Text] [Related]
38. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. Ged Y; Lee CH Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355 [TBL] [Abstract][Full Text] [Related]
39. Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003. Dudek AZ; Liu LC; Gupta S; Logan TF; Singer EA; Joshi M; Zakharia YN; Lang JM; Schwarz JK; Al-Janadi A; Alva AS J Clin Oncol; 2020 Apr; 38(11):1138-1145. PubMed ID: 32097091 [TBL] [Abstract][Full Text] [Related]
40. Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. Yonemori K; Yunokawa M; Ushijima K; Sakata J; Shikama A; Minobe S; Usami T; Enomoto T; Takehara K; Hasegawa K; Yamagami W; Yamamoto K; Han S; Dutta L; Orlowski R; Miura T; Makker V; Fujiwara K Cancer Sci; 2022 Oct; 113(10):3489-3497. PubMed ID: 35612971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]